Ken Song, Ablaze chairman and RayzeBio CEO
November 30, 2021 07:24 AM ESTUpdated December 3, 02:11 AM
Financing
Startups
China

Af­ter Big Phar­ma sparked in­ter­est in the US, Ablaze looks to bring ra­dio­phar­ma­ceu­ti­cals over­seas

Nicole DeFeudis

Editor

Thanks in part to in­ter­est from Big Phar­ma play­ers like Bay­er and No­var­tis over the last decade, there’s been no short­age in cash for new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times